|
1.
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar
|
|
2.
|
Poon RT, Fan ST, Lo CM, Liu CL and Wong J:
Intrahepatic recurrence after curative resection of hepatocellular
carcinoma: long-term results of treatment and prognostic factors.
Ann Surg. 229:216–222. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
El-Serag HB and Mason AC: Rising incidence
of hepatocellular carcinoma in the United States. N Engl J Med.
340:745–750. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Llovet JM and Bruix J: Novel advancements
in the management of hepatocellular carcinoma in 2008. J Hepatol.
48(Suppl 1): S20–S37. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Bruix J and Sherman M: Management of
hepatocellular carcinoma. Hepatology. 42:1208–1236. 2005.
View Article : Google Scholar
|
|
6.
|
Mulcahy MF: Management of hepatocellular
cancer. Curr Treat Options Oncol. 6:423–435. 2005. View Article : Google Scholar
|
|
7.
|
Bosch FX, Ribes J, Diaz M and Cleries R:
Primary liver cancer: worldwide incidence and trends.
Gastroenterology. 127:S5–S16. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Verslype C, Van Cutsem E, Dicato M, Arber
N, Berlin JD, Cunningham D, De Gramont A, Diaz-Rubio E, Ducreux M,
Gruenberger T, Haller D, Haustermans K, Hoff P, Kerr D, Labianca R,
Moore M, Nordlinger B, Ohtsu A, Rougier P, Scheithauer W, Schmoll
HJ, Sobrero A, Tabernero J and van de Velde C: The management of
hepatocellular carcinoma. Current expert opinion and
recommendations derived from the 10th World Congress on
Gastrointestinal Cancer, Barcelona, 2008. Ann Oncol. 20(Suppl 7):
vii1–vii6. 2009. View Article : Google Scholar
|
|
9.
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J,
Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D and Guan Z:
Efficacy and safety of sorafenib in patients in the Asia-Pacific
region with advanced hepatocellular carcinoma: a phase III
randomised, double-blind, placebo-controlled trial. Lancet Oncol.
10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Kim R, Byrne MT, Tan A and Aucejo F: What
is the indication for sorafenib in hepatocellular carcinoma? A
clinical challenge. Oncology. 25:283–295. 2011.PubMed/NCBI
|
|
11.
|
Yap TA, Garrett MD, Walton MI, Raynaud F,
de Bono JS and Workman P: Targeting the PI3K-AKT-mTOR pathway:
progress, pitfalls and promises. Curr Opin Pharmacol. 8:393–412.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Ward CS, Venkatesh HS, Chaumeil MM,
Brandes AH, Vancriekinge M, Dafni H, Sukumar S, Nelson SJ, Vigneron
DB, Kurhanewicz J, James CD, Haas-Kogan DA and Ronen SM:
Noninvasive detection of target modulation following
phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C
magnetic resonance spectroscopy. Cancer Res. 70:1296–1305. 2010.
View Article : Google Scholar
|
|
13.
|
Fry MJ: Phosphoinositide 3-kinase
signalling in breast cancer: how big a role might it play? Breast
Cancer Res. 3:304–312. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Dunlop EA and Tee AR: Mammalian target of
rapamycin complex 1: signalling inputs, substrates and feedback
mechanisms. Cell Signal. 21:827–835. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Sparks CA and Guertin DA: Targeting mTOR:
prospects for mTOR complex 2 inhibitors in cancer therapy.
Oncogene. 29:3733–3744. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Nakanishi K, Sakamoto M, Yamasaki S, Todo
S and Hirohashi S: Akt phosphorylation is a risk factor for early
disease recurrence and poor prognosis in hepatocellular carcinoma.
Cancer. 103:307–312. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Boyault S, Rickman DS, de Reyniès A,
Balabaud C, Rebouissou S, Jeannot E, Hérault A, Saric J, Belghiti
J, Franco D, Bioulac-Sage P, Laurent-Puig P and Zucman-Rossi J:
Transcriptome classification of HCC is related to gene alterations
and to new therapeutic targets. Hepatology. 45:42–52. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Sahin F, Kannangai R, Adegbola O, Wang J,
Su G and Torbenson M: mTOR and P70 S6 kinase expression in primary
liver neoplasms. Clin Cancer Res. 10:8421–8425. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Powis G, Bonjouklian R, Berggren MM,
Gallegos A, Abraham R, Ashendel C, Zalkow L, Matter WF, Dodge J,
Grindey G and Vlahos CJ: Wortmannin, a potent and selective
inhibitor of phosphatidylinositol-3-kinase. Cancer Res.
54:2419–2423. 1994.PubMed/NCBI
|
|
21.
|
Vlahos CJ, Matter WF, Hui KY and Brown RF:
A specific inhibitor of phosphatidylinositol 3-kinase,
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol
Chem. 269:5241–5248. 1994.PubMed/NCBI
|
|
22.
|
West KA, Castillo SS and Dennis PA:
Activation of the PI3K/Akt pathway and chemotherapeutic resistance.
Drug Resist Updat. 5:234–248. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Workman P: Inhibiting the phosphoinositide
3-kinase pathway for cancer treatment. Biochem Soc Trans.
32:393–396. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Hu XT and Owens MA: Multiplexed protein
quantification in maize leaves by liquid chromatography coupled
with tandem mass spectrometry: an alternative tool to immunoassays
for target protein analysis in genetically engineered crops. J
Agric Food Chem. 59:3551–3558. 2011. View Article : Google Scholar
|
|
25.
|
Kim O, Jeong Y, Lee H, Hong SS and Hong S:
Design and synthesis of imidazopyridine analogues as inhibitors of
phosphoinositide 3-kinase signaling and angiogenesis. J Med Chem.
54:2455–2466. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Malumbres M, Pevarello P, Barbacid M and
Bischoff JR: CDK inhibitors in cancer therapy: what is next? Trends
Pharmacol Sci. 29:16–21. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Semenza GL: Expression of
hypoxia-inducible factor 1: mechanisms and consequences. Biochem
Pharmacol. 59:47–53. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Shiojima I and Walsh K: Role of Akt
signaling in vascular homeostasis and angiogenesis. Circ Res.
90:1243–1250. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Sommers I and Baskin D: Sex, race, age and
violent offending. Violence Vict. 7:191–201. 1992.PubMed/NCBI
|
|
30.
|
O’Brien C, Wallin JJ, Sampath D,
GuhaThakurta D, Savage H, Punnoose EA, Guan J, Berry L, Prior WW,
Amler LC, Belvin M, Friedman LS and Lackner MR: Predictive
biomarkers of sensitivity to the phosphatidylinositol 3’ kinase
inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer
Res. 16:3670–3683. 2010.
|
|
31.
|
Yang L, Dan HC, Sun M, Liu Q, Sun XM,
Feldman RI, Hamilton AD, Polokoff M, Nicosia SV, Herlyn M, Sebti SM
and Cheng JQ: Akt/protein kinase B signaling inhibitor-2, a
selective small molecule inhibitor of Akt signaling with antitumor
activity in cancer cells overexpressing Akt. Cancer Res.
64:4394–4399. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Schultz RM, Merriman RL, Andis SL,
Bonjouklian R, Grindey GB, Rutherford PG, Gallegos A, Massey K and
Powis G: In vitro and in vivo antitumor activity of the
phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer
Res. 15:1135–1139. 1995.PubMed/NCBI
|
|
33.
|
Rowinsky EK: Targeting the molecular
target of rapamycin (mTOR). Curr Opin Oncol. 16:564–575. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
LoPiccolo J, Granville CA, Gills JJ and
Dennis PA: Targeting Akt in cancer therapy. Anticancer Drugs.
18:861–874. 2007.
|
|
35.
|
Ashe PC and Berry MD: Apoptotic signaling
cascades. Prog Neuropsychopharmacol Biol Psychiatry. 27:199–214.
2003. View Article : Google Scholar
|
|
36.
|
Belozerov VE and Van Meir EG: Hypoxia
inducible factor-1: a novel target for cancer therapy. Anticancer
Drugs. 16:901–909. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Hamedi M, Wigenius J, Tai FI, Björk P and
Aili D: Polypeptide-guided assembly of conducting polymer
nanocomposites. Nanoscale. 2:2058–2061. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Ben-Shoshan M, Amir S, Dang DT, Dang LH,
Weisman Y and Mabjeesh NJ: 1alpha,25-dihydroxyvitamin D3
(Calcitriol) inhibits hypoxia-inducible factor-1/vascular
endothelial growth factor pathway in human cancer cells. Mol Cancer
Ther. 6:1433–1439. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
López-Lázaro M: Hypoxia-inducible factor 1
as a possible target for cancer chemoprevention. Cancer Epidemiol
Biomarkers Prev. 15:2332–2335. 2006.PubMed/NCBI
|
|
40.
|
Zhong H, Chiles K, Feldser D, Laughner E,
Hanrahan C, Georgescu MM, Simons JW and Semenza GL: Modulation of
hypoxia-inducible factor 1alpha expression by the epidermal growth
factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human
prostate cancer cells: implications for tumor angiogenesis and
therapeutics. Cancer Res. 60:1541–1545. 2000.
|
|
41.
|
Mazure NM, Chen EY, Laderoute KR and
Giaccia AJ: Induction of vascular endothelial growth factor by
hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt
signaling pathway in Ha-ras-transformed cells through a hypoxia
inducible factor-1 transcriptional element. Blood. 90:3322–3331.
1997.
|
|
42.
|
Papetti M and Herman IM: Mechanisms of
normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol.
282:C947–C970. 2002. View Article : Google Scholar : PubMed/NCBI
|
